The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib.

ABSTRACT:

Introduction

Clear-cell renal cell carcinoma (ccRCC) is the sixth most common malignancy in men in North America. Since ccRCC is a malignancy dependent on neovascularization, current first line systemic therapies like sunitinib, target the formation of new vessels allowing nutrient deprivation and cell death. However, recent studies have shown that patients develop resistance after approximately 1 year of treatment and show disease progression while on therapy. Therefore, we propose to identify the protein(s) responsible for increased migration with the aim of developing a new therapy that will target the identified protein and potentially slow down the progression of the disease.

Material and methods

Human renal cancer cell lines (Caki-1, Caki-2, ACHN) were treated with inc

SUBMITTER: Frees S 

PROVIDER: S-EPMC5978253 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature